drugset
drugset / Trial / NCT07390838

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

NCT07390838 ↗

Phase 1 Recruiting 150 enrolled Nanjing Sanhome Pharmaceutical, Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors

Timeline

Start
2025-05-16
Primary completion
2026-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SH009 Unknown 40 mg/kg —

Indications

breast cancer esophageal cancer gastric cancer head and neck squamous cell carcinoma liver cancer non-small cell lung carcinoma